Navigation Links
Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting
Date:12/2/2009

ti-Myeloma Therapy (MM Tx). 51st American Society of Hematology Annual Meeting and Exposition, New Orleans, LA. December 5-8, 2009.

(9) Zometa Prescribing Information. March 2008.

(10) Tasigna (nilotinib) Prescribing Information. East Hanover, New Jersey, USA: Novartis Pharma. http://www.pharma.us.novartis.com/product/pi/pdf/tasigna.pdf.

(11) Gleevec (imatinib mesylate) tablets prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; November 2008.


Novartis Media Relations

Media only:                              Investors only:
Megan Humphrey                           Richard Jarvis
Novartis Oncology                        Novartis Corporation
P: +1 862 778 6724                       P: +1 212 830 2433

Dana Kahn Cooper
P: +1 732 817 1800
F: +1 732 817 1834

e-mail                                   e-mail
media.relations@novartis.com             investor.relations@novartis.com

SOURCE Novartis


'/>"/>
SOURCE Novartis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related medicine technology :

1. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
2. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
3. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
4. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
5. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
6. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
7. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
8. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
9. DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study
10. FASgen Announces Significant Milestone in Its Cancer Drug Development Program
11. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... California , 20 de octubre de 2014 ... en el campo de la pulmonología intervencional, anunció ... Estudio RENEW, casi 3 meses antes de lo ... de exención de dispositivo de investigación (IDE) aprobada ... para el sistema de espiral de reducción de ...
(Date:10/20/2014)... Colo. , Oct. 20, 2014  Luoxis ... (NYSE MKT: AMPE), today announced that its academic ... clinical and research potential for its novel RedoxSYS ... potential (ORP) in the body in response to ... value of ORP as a clinical marker will ...
(Date:10/20/2014)... 20, 2014 Valeritas, Inc., a leader in ... with Type 2 diabetes, announced today that it has ... The award was presented October 16 th at ... Ohio . The Cardinal Health ... variety of metrics specifically targeted at the importance of ...
Breaking Medicine Technology:PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3
... - CytRx Corporation,(NASDAQ:CYTR) today announced positive results ... lead drug candidate,arimoclomol significantly accelerated the recovery ... rat model of stroke, even when,treatment was ... stroke was,induced. These data confirm and expand ...
... PARK, N.C.--(BUSINESS WIRE)--Apr 3, 2007 -,Icagen, Inc. (NASDAQ: ... the independent Data Monitoring Committee,("DMC") of the Company's ... of sickle cell disease in adults, the,DMC recommended ... low,probability of achieving a reduction in crisis rate, ...
Cached Medicine Technology:CytRx Announces Positive Results of Arimoclomol in Preclinical,Stroke Recovery Studies 2CytRx Announces Positive Results of Arimoclomol in Preclinical,Stroke Recovery Studies 3CytRx Announces Positive Results of Arimoclomol in Preclinical,Stroke Recovery Studies 4CytRx Announces Positive Results of Arimoclomol in Preclinical,Stroke Recovery Studies 5Icagen Terminates Phase III ASSERT Study 2Icagen Terminates Phase III ASSERT Study 3
(Date:10/20/2014)... October 20, 2014 Women’s health specialist, ... Obstetrics & Gynecology of Columbus, Inc., A Division of ... services to more than 100,000 patients annually. Dr. Murphy ... ages and stages of a women’s life. She is ... in Westerville and Dublin. , Dr. Murphy offers ...
(Date:10/20/2014)... Indianapolis, IN (PRWEB) October 20, 2014 ... Quick Start, a secure cloud solution that enables ... advantage of the ultimate healthcare-specific customer relationship management ... to meet the unique needs of the healthcare ... healthcare experience for providers and patients by combining ...
(Date:10/20/2014)... October 20, 2014 JZ Fitness, an ... coaching, corporate wellness programming, authorship, international lecturing and community ... to announce the release of the JZ Fitness nutrition ... years of coaching thousands of individuals on nutrition, Jenn ... that does not require calorie counting or cumbersome food ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Principle Business ... takes pride in manufacturing top-of-the-line absorbent products. The ... of its most popular brand, Tranquility® Premium Protection absorbent ... a new website, gave its packaging a new look, ... the brand message to the public. , The new ...
(Date:10/20/2014)... PA (PRWEB) October 20, 2014 ... Matthew Voicheck as Assistant Director of their ... role in managing the innovative turnkey drug sourcing, ... , Matthew brings over 12 years of industry ... joins Myoderm at the peak of their international ...
Breaking Medicine News(10 mins):Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2
... guideline on colorectal cancer screening released today by ... health care organizations, including the American College of ... (ASGE) and the American Cancer Society (ACS), offers ... and states a strong preference for screening tests ...
... National Naval Medical Center in Bethesda, Maryland Coincides, With Sleep ... ... Awareness Week, DALLAS, March 6 /PRNewswire/ - The ... importance for Dr. Keith Thornton,third-generation Dallas dentist and recognized expert on the ...
... Centers, Inc.,("GNC" or the "Company"), the largest global ... results for the,quarter and year ended Dec. 31, ... indirect wholly-owned subsidiary,of GNC Parent LLC, which was ... Management LLC and Ontario Teachers, Pension Plan Board. ...
... CARLSBAD, Calif., March 6 Genoptix, Inc.,(Nasdaq: GXDX ... participation in the Cowen and Company 28th Annual Health,Care ... Boston, Mass.,March 17 - 20, 2008., Dr. Tina ... COO, will present at the conference on Monday, March ...
... Quarterly Revenue and Returns to Profitability ... First Half 2008 Financial Guidance ... Time, NASHUA, N.H., March 6 iCAD, Inc. (Nasdaq:,ICAD), ... detection of cancer, today announced financial,results for the fourth quarter ...
... Adjusted EBITDA up 33%, TORONTO, March 6 /PRNewswire-FirstCall/ ... of products and services to the global life,sciences markets, ... MDS reported net revenues of $296 million, net income ... of $0.14.,Adjusted EBITDA rose to $40 million, up from ...
Cached Medicine News:Health News:New guidelines update recommendations on colorectal cancer screening 2Health News:New guidelines update recommendations on colorectal cancer screening 3Health News:New guidelines update recommendations on colorectal cancer screening 4Health News:Dallas Dentist Trains Navy Dentists on New Therapy to Treat Snoring and Obstructive Sleep Apnea 2Health News:General Nutrition Centers, Inc. Reports Fourth Quarter and Full Year 2007 Results 2Health News:General Nutrition Centers, Inc. Reports Fourth Quarter and Full Year 2007 Results 3Health News:General Nutrition Centers, Inc. Reports Fourth Quarter and Full Year 2007 Results 4Health News:General Nutrition Centers, Inc. Reports Fourth Quarter and Full Year 2007 Results 5Health News:General Nutrition Centers, Inc. Reports Fourth Quarter and Full Year 2007 Results 6Health News:General Nutrition Centers, Inc. Reports Fourth Quarter and Full Year 2007 Results 7Health News:General Nutrition Centers, Inc. Reports Fourth Quarter and Full Year 2007 Results 8Health News:General Nutrition Centers, Inc. Reports Fourth Quarter and Full Year 2007 Results 9Health News:General Nutrition Centers, Inc. Reports Fourth Quarter and Full Year 2007 Results 10Health News:General Nutrition Centers, Inc. Reports Fourth Quarter and Full Year 2007 Results 11Health News:Genoptix Announces Participation at Cowen and Company 28th Annual Health Care Conference 2Health News:iCAD Reports Fourth Quarter and Full Year 2007 Financial Results 2Health News:iCAD Reports Fourth Quarter and Full Year 2007 Financial Results 3Health News:iCAD Reports Fourth Quarter and Full Year 2007 Financial Results 4Health News:iCAD Reports Fourth Quarter and Full Year 2007 Financial Results 5Health News:iCAD Reports Fourth Quarter and Full Year 2007 Financial Results 6Health News:iCAD Reports Fourth Quarter and Full Year 2007 Financial Results 7Health News:iCAD Reports Fourth Quarter and Full Year 2007 Financial Results 8Health News:iCAD Reports Fourth Quarter and Full Year 2007 Financial Results 9Health News:MDS Reports First Quarter 2008 Results 2Health News:MDS Reports First Quarter 2008 Results 3Health News:MDS Reports First Quarter 2008 Results 4Health News:MDS Reports First Quarter 2008 Results 5Health News:MDS Reports First Quarter 2008 Results 6Health News:MDS Reports First Quarter 2008 Results 7Health News:MDS Reports First Quarter 2008 Results 8Health News:MDS Reports First Quarter 2008 Results 9Health News:MDS Reports First Quarter 2008 Results 10Health News:MDS Reports First Quarter 2008 Results 11Health News:MDS Reports First Quarter 2008 Results 12Health News:MDS Reports First Quarter 2008 Results 13
... Vitatron T-series is a new top-line range ... bradycardia and Atrial Fibrillation (AF). Because the ... for AF, the treatment of AF is ... digital technology the heart rhythm is monitored ...
... Xper is the perfect partner for growing ... systems are scalable to meet your needs ... means that your Allura Xper FD20 system ... use. Openness to new technologies allows you ...
... MAX Cooling Power, Deeper Lesions ... arrhythmias, including atrial flutter, Freezor MAX is ... catheter with an 8mm ablation tip was ... is connected to the same cryoconsole as ...
... Volume coverage, not slices, changes the ... are performed. The LightSpeed VCT Series of ... making the imaging of difficult patients or ... groundbreaking technology opens the door to new ...
Medicine Products: